Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan

Phase 2CompletedNCT00212693

Ono Pharmaceutical Co., Ltd.165 enrolled

Overview

The purpose of this study is to evaluate the efficacy and safety of ONO-2506PO in patients with Parkinson's Disease

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

165

Conditions

Parkinson's Disease

Interventions

ONO-2506PODRUG

Eligibility

Sex: ALLMin age: 20 YearsMax age: 79 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Diagnosis of Parkinson's disease 2. Stage 2 - Stage 4 of revised Hoehn \& Yahr severity score 3. Taking L-dopa/DCI without changing dose and regimen 4. Having motor complication 5. Other inclusion criteria as specified in the study protocol Exclusion Criteria: 1. Previous participation in ONO-2506PO or ONO-2506 protocol 2. Previous brain surgery for Parkinson's disease 3. Presence or history of serious cardiac disease 4. Other exclusion criteria as specified in the study protocol

Outcomes

Primary Outcomes

Unified Parkinson's disease rating scale (Part III)

Secondary Outcomes

Unified Parkinson's disease rating scale (Part I, II, IV and total), revised Hoehn & Yahr severity score and off time

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.